An abnormal amyloid PET scan means the scan shows moderate-to-frequent beta-amyloid plaques in the brain. An amyloid PET scan is brain imaging that maps those plaques, and the next step is clinical work to link the scan to symptoms and care choices. A positive result alone does not diagnose Alzheimer's disease by itself. The clinician correlates it with history, examination, thinking tests, MRI, and labs, then decides on staging or treatment planning.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Does an abnormal result mean Alzheimer's disease?
- What will the clinician check next?
- Will you need more biomarker testing?
- Could this result lead to amyloid-directed treatment?
- What safety and coverage steps come with treatment planning?
Does an abnormal result mean Alzheimer's disease?
A positive scan estimates moderate-to-frequent neuritic plaque density. According to the U.S. FDA Amyvid prescribing information, similar plaque burden also occurs in other neurologic disorders and in cognitively normal older adults, so the scan alone does not establish Alzheimer's the FDA Amyvid label.
Biological framing is narrower. Under the 2024 Alzheimer's Association Workgroup revised criteria, one abnormal Core 1 biomarker such as amyloid PET can establish biological Alzheimer's disease the Association's revised criteria announcement. Core 2 biomarkers then refine biological staging and prognosis.
What will the clinician check next?
The clinician reviews when symptoms started, how they progressed, daily function, medicines, and other conditions. That visit usually includes a neurologic examination, formal cognitive testing, brain MRI, and blood and other labs to exclude mimics.
This follow-up also tests whether the scan fits the syndrome. A strongly positive scan with a matching amnestic course points one way. A positive scan with an abrupt vascular course, untreated sleep apnea, depression, or medication effects points toward mixed causes or another primary cause.
Will you need more biomarker testing?
Often yes, when the added result will change care. The Alzheimer's Association and SNMMI advise ordering amyloid and tau PET only when the result will directly change care, including clarifying unexplained impairment or therapy eligibility.
Practical add-ons after abnormal amyloid PET include tau PET, spinal-fluid testing, or blood p-tau217 for staging and treatment planning. Tau information helps place disease stage and prognosis and sharpens the discussion about monitoring and therapy.
Could this result lead to amyloid-directed treatment?
Confirmed amyloid positivity plus mild cognitive impairment or mild dementia makes a patient potentially eligible for FDA-approved amyloid-directed therapies lecanemab and donanemab. Those drugs modestly slow decline rather than cure dementia.
Eligibility screening is specific. Patients need confirmation of stage, review of bleeding risks, other medical fitness, and brain imaging review before any prescription decision.
- Confirm mild cognitive impairment or mild dementia stage
- Confirm amyloid positivity on record
- Complete APOE ε4 testing before lecanemab
- Obtain a recent baseline brain MRI and plan scheduled MRI surveillance during lecanemab treatment
What safety and coverage steps come with treatment planning?
FDA lecanemab labeling requires APOE ε4 testing before treatment because homozygotes face higher ARIA swelling-or-bleed risk, plus a recent baseline brain MRI and scheduled MRI surveillance during treatment the FDA Leqembi label. Report new headache, confusion, dizziness, vision change, or weakness promptly during that monitoring period. Check payment before scheduling added scans.
CMS retired national coverage-with-evidence-development for amyloid PET on Oct. 13, 2023, ending NCD 220.6.20 and leaving coverage decisions to regional Medicare contractors the CMS coverage decision memo. Patients must verify local coverage with their Medicare contractor and hospital billing office.





